Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Inclusion Criteria: * Children of any gender * Aged 2 month to 12 years * Diagnosed with septic shock * Admitted to the pediatric intensive care unit Exclusion Criteria: * Known adrenal insufficiency or congenital adrenal hyperplasia * History of corticosteroid use within the past 7 days * Terminal illness or "do-not-resuscitate (DNR)" status * Severe immunocompromise (e.g., advanced malignancy, HIV stage IV) * Known allergy to hydrocortisone